aTYR PHARMA INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2005-01-01

Employees: 59

Market Cap: $141.7M

Website: http://www.atyrpharma.com

Clinical Trials

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Phase 2

Recruiting

Conditions: Interstitial Lung Disease

Interventions: Drug: efzofitimod 450 mg
Drug: efzofitimod 270 mg
Drug: Placebo

First Posted Date: 2023-06-07

Last Posted Date: 2024-07-31

Lead Sponsor: aTyr Pharma, Inc.

Target Recruit Count: 25

Registration Number: NCT05892614

Locations: 🇺🇸
aTyr Investigative Site, Richmond, Virginia, United States

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Phase 3

Active, not recruiting

Conditions: Pulmonary Sarcoidosis

Interventions: Drug: Placebo
Drug: Efzofitimod 5 mg/kg
Drug: Efzofitimod 3 mg/kg

First Posted Date: 2022-06-10

Last Posted Date: 2024-12-18

Lead Sponsor: aTyr Pharma, Inc.

Target Recruit Count: 268

Registration Number: NCT05415137

Locations: 🇬🇧
aTyr Investigative Site, London, United Kingdom
🇯🇵
Kyorin Investigative Site, Tokyo, Japan

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

Phase 2

Completed

Conditions: SARS-CoV-2 (COVID-19) Severe Pneumonia

Interventions: Drug: Efzofitimod 3 mg/kg
Drug: Placebo
Drug: Efzofitimod 1 mg/kg

First Posted Date: 2020-06-02

Last Posted Date: 2023-08-18

Lead Sponsor: aTyr Pharma, Inc.

Target Recruit Count: 36

Registration Number: NCT04412668

Locations: 🇺🇸
aTyr Investigative Site, Toledo, Ohio, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 5 locations

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Phase 1

Completed

Conditions: Pulmonary Sarcoidosis

Interventions: Biological: Efzofitimod 3.0 mg/kg or Placebo
Biological: Efzofitimod 5.0 mg/kg or Placebo
Biological: Efzofitimod 1.0 mg/kg or Placebo

First Posted Date: 2019-01-31

Last Posted Date: 2023-07-18

Lead Sponsor: aTyr Pharma, Inc.

Target Recruit Count: 37

Registration Number: NCT03824392

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
aTyr Investigative Site, Chicago, Illinois, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 10 locations

Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

Phase 1

Completed

Conditions: Limb Girdle Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy

Interventions: Drug: ATYR1940

First Posted Date: 2016-07-19

Last Posted Date: 2023-12-22

Lead Sponsor: aTyr Pharma, Inc.

Target Recruit Count: 8

Registration Number: NCT02836418

Locations: 🇮🇹
Foundation IRCCS Neurological Institute Carlo, Milan, Italy
🇩🇰
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
🇺🇸
Stanford University, Stanford, California, United States

and more 2 locations

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy

Phase 1

Completed

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)

Interventions: Biological: ATYR1940

First Posted Date: 2015-11-13

Last Posted Date: 2023-10-19

Lead Sponsor: aTyr Pharma, Inc.

Target Recruit Count: 8

Registration Number: NCT02603562

Locations: 🇺🇸
OSU Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
University of Iowa Children's Hospital, Iowa City, Iowa, United States
🇺🇸
Stanford University, Stanford, California, United States

and more 4 locations

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

Phase 1

Completed

Conditions: Limb-Girdle Muscular Dystrophies
Facioscapulohumeral Muscular Dystrophy

Interventions: Biological: ATYR1940
Biological: Placebo

First Posted Date: 2015-10-19

Last Posted Date: 2023-10-19

Lead Sponsor: aTyr Pharma, Inc.

Target Recruit Count: 18

Registration Number: NCT02579239

Locations: 🇺🇸
University of California, Irvine, ALS and Neuromuscular Center, Irvine, California, United States
🇫🇷
Institut de Myologie, Hôpital Pitié-Salpêtrière, Paris, France
🇺🇸
OSU Wexner Medical Center, Columbus, Ohio, United States

and more 3 locations

Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension

Phase 1

Completed

Conditions: Facioscapulohumeral Muscular Dystrophy

Interventions: Biological: ATYR1940

First Posted Date: 2015-08-24

Last Posted Date: 2023-08-18

Lead Sponsor: aTyr Pharma, Inc.

Target Recruit Count: 9

Registration Number: NCT02531217

Locations: 🇳🇱
aTyr Pharma Investigative Site, Nijmegen, Netherlands

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

Phase 1

Completed

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)

Interventions: Biological: Placebo
Biological: ATYR1940

First Posted Date: 2014-09-12

Last Posted Date: 2021-08-11

Lead Sponsor: aTyr Pharma, Inc.

Target Recruit Count: 20

Registration Number: NCT02239224

Locations: 🇳🇱
aTyr Pharma Investigative Site, Nijmegen, Netherlands

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy